Defined-Factor Reprogramming to Proliferative Cardiac Progenitor Cells

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing methods for reprogramming somatic cells to induced cardiomyocytes (iCM) are limited by their lack of proliferative capacity and multipotency, and the ethical and practical challenges of using pluripotent stem cells for producing induced cardiac progenitor cells (iCPC) hinder therapeutic and research applications.

Innovation Solution

A method involving the expression of defined factors, such as early cardiac transcription factors like Mesp1, Baf60c, Nkx2.5, Gata4, and Tbx5, in somatic cells, followed by separation of induced cardiac progenitor cells (iCPC) using cell sorting or morphological differences, to achieve stable reprogramming into proliferative and multipotent iCPCs.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If pluripotent stem cells (ESC or iPSC) are used to produce induced cardiac progenitor cells (iCPC), then multipotency and proliferative capacity are achieved, but ethical considerations and time-consuming differentiation processes hinder practical application

Engineering Contradiction:

ImprovemultipotencyVSAvoidpractical applicability

Core Design Contradiction:

Adaptability or versatilityVSEase of manufacture

Solution Approach 1:

The patent segments the complex differentiation process of pluripotent stem cells into a direct reprogramming pathway. Instead of allowing cells to pass through multiple intermediate stages (including pluripotent state), the invention directly converts fibroblasts to iCPCs through targeted overexpression of cardiac transcription factors, thereby eliminating ethical concerns and reducing time while preserving multipotency

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent applies preliminary action by pre-selecting and overexpressing specific cardiac transcription factors (Mesp1, Nkx2-5, Gata4, Tbx5) in fibroblasts before any differentiation occurs. This preliminary genetic programming directs the cells along a predetermined cardiac progenitor pathway, bypassing the need for extensive differentiation protocols required by pluripotent stem cells

Inventive Principle:

Principle #10Preliminary action

2Reliability

If induced cardiomyocytes (iCM) are produced from somatic cells, then therapeutic cardiomyocytes are obtained, but lack of proliferative capacity limits the available source for therapeutic use

Engineering Contradiction:

Improvetherapeutic utilityVSAvoidproliferative capacity

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent inverts the conventional approach by not directly differentiating somatic cells to cardiomyocytes (iCM), but instead first reprogramming them to a cardiac progenitor state (iCPC) that inherently possesses proliferative capacity. These iCPCs can then self-renew and differentiate into iCMs in vivo, thereby solving the productivity limitation of direct iCM reprogramming

Inventive Principle:

Principle #13The other way round (Inversion)

Solution Approach 2:

The patent introduces cardiac progenitor cells (iCPCs) as an intermediary state between fibroblasts and functional cardiomyocytes. This intermediary population maintains proliferative capabilities while being committed to the cardiac lineage, serving as a renewable source that can continuously generate therapeutic cardiomyocytes

Inventive Principle:

Principle #24Intermediary (Mediator)

3Adaptability or versatility

If a defined set of cardiac transcription factors is overexpressed in somatic cells, then direct reprogramming to iCPC is achieved, but the complexity of factor delivery and combination optimization increases

Engineering Contradiction:

Improvereprogramming efficiencyVSAvoiddelivery system complexity

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent merges multiple cardiac transcription factor delivery systems into a single integrated approach. By combining Mesp1, Nkx2-5, Gata4, and Tbx5 factors delivered through a unified viral or non-viral vector system, the invention simplifies the overall delivery complexity while maintaining high reprogramming efficiency to iCPCs

Inventive Principle:

Principle #5Merging (Combining)

Data Source

PatentUS12435313B2Lineage reprogramming to induced cardiac progenitor cells (iCPC) by defined factors

Publication Date: 2025.10.07 WISCONSIN ALUMNI RES FOUND

AI summary

Animal cells, notably adult fibroblasts, are advantageously reprogrammed in direct lineage reprogramming methods using defined factors to produce proliferative and multipotent induced cardiac progenitor cells (iCPC). The iCPC thus produced can be differentiated under suitable differentiation conditions to cardiac lineage cells including cardiomyocytes, smooth muscle cells, and endothelial cells, as evidenced by expression of lineage specific markers. Sets of factors effective in combination to reprogram the fibroblasts can include a set that includes some or all of 5 factors (Mesp1, Baf60c, Nkx2.5, Gata4, Tbx5), a set that includes some or all of 11 factors (Mesp1, Mesp2, Gata4, Gata6, Baf60c, SRF, Isl1, Nkx2.5, Irx4, Tbx5, Tbx20), a set that includes some or all of 18 factors (T, Mesp1, Mesp2, Tbx5, Tbx20, Isl1, Gata4, Gata6, Irx4, Nkx2.5, Hand1, Hand2, Tbx20, Tbx18, Tip60, Baf60c, SRF, Hey2), and a set that includes some or all of 22 factors (T, Mesp1, Mesp2, Tbx5, Tbx20, Isl1, Gata4, Gata6, Irx4, Nkx2.5, Hand1, Hand2, Tbx20, Tbx18, Tip60, Baf60c, SRF, Hey2, Oct4, Klf4, Sox2, L-myc).